Thanh bên bài viết
Số lượt xem chi tiết bài báo: 20
Antimicrobial susceptibility profile of Staphylococcus haemolyticus isolated from Vietnamese cancer patients over 4 years
Nội dung chính của bài viết
Tóm tắt
S. haemolyticus is frequently colonizing the hospital environment and resistance to multiple antibiotics. The antimicrobial-resistant data of S. haemolyticus from Vietnamese cancer patients are limited. This study aims to evaluate the antimicrobial susceptibility profile of 41 S. haemolyticus isolated from Vietnamese cancer patients over a period of 4 years.
The rate of methicillin-resistant and multidrug-resistant was 48.8% (20/41) and 95.1% (39/41), respectively. The most frequent sample was blood (65.9%, 27/41), and the second most frequent was sputum (12.2%, 5/41).
All isolates were susceptible to quinupristin-dalfopristin, linezolid, tigecycline, and nitrofurantoin, and about 97% of isolates were susceptible to vancomycin. Approximately 96.88% of isolates were resistant to Benzylpenicillin and oxacillin, 93.75% were resistant to erythromycin, and 90.63% were resistant to Ciprofloxacin and Levofloxacin. The high level of methicillin and multidrug-resistant and reduced susceptibility to many antibiotics are causes of concern since they further narrow down the therapeutic options.
Quinupristin-dalfopristin, linezolid, tigecycline, nitrofurantoin, and vancomycin are effective against S. haemolyticus infection in Vietnamese cancer patients at Vietnam National Cancer Hospital/Tan Trieu Base. Further studies are needed to surveillance bacterial resistance to guide antimicrobial therapy, reduce antimicrobial resistance rates, and improve the Vietnamese cancer patient’s care.
Chi tiết bài viết
Từ khóa
S. haemolyticus, MRSA, MDR, Vietnamese, cancer
Tài liệu tham khảo
2. Yu MH, Chen YG, Yu YS, Chen CL, Li LJ. Antimicrobial resistance and molecular characterization of Staphylococcus haemolyticus in a Chinese hospital. European Journal of Clinical Microbiology & Infectious Diseases: Official publication of the European Society of Clinical Microbiology. 2010;29(5):613-6.
3. Shi MM, Monsel A, Rouby JJ, Xu YP, Zhu YG, Qu JM. Inoculation Pneumonia Caused by Coagulase Negative Staphylococcus. Frontiers in microbiology. 2019;10:2198.
4. Pinheiro L, Brito CI, Pereira VC, Oliveira A, Bartolomeu AR, Camargo CH, et al. Susceptibility Profile of Staphylococcus epidermidis and Staphylococcus haemolyticus Isolated from Blood Cultures to Vancomycin and Novel Antimicrobial Drugs over a Period of 12 Years. Microbial drug resistance. 2016;22(4):283-93.
5. Ahmed NH, Baruah FK, Grover RK. Staphylococcal Blood Stream Infections in Cancer Patients. Ann Med Health Sci Res. 2015;5(3):226-7.
6. Pain M, Hjerde E, Klingenberg C, Cavanagh JP. Comparative Genomic Analysis of Staphylococcus Haemolyticus Reveals Key to Hospital Adaptation and Pathogenicity. Frontiers in microbiology. 2019;10:2096.
7. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrobial agents and chemotherapy. 2011;55(8):3684-90.
8. Manfredi R, Sabbatani S. Novel pharmaceutical molecules against emerging resistant gram-positive cocci. Braz J Infect Dis. 2010;14(1):96-108.